RCMT
RCM Technologies, Inc.20.92
-0.32-1.51%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
155.03MP/E (TTM)
12.23Basic EPS (TTM)
1.71Dividend Yield
0%Recent Filings
8-K
Credit line up to $75M
RCM Technologies boosted its revolving credit line to $75M from $65M via Amendment No. 1 with Citizens Bank, effective February 20, 2026, through August 31, 2026. It reverts to $65M on September 1, with excess loans due immediately. Temporary liquidity flexes for working capital. Reaffirmed all liens.
8-K
Stockholders approve equity plan
RCM Technologies stockholders approved the 2025 Omnibus Equity Compensation Plan on December 18, 2025, authorizing 1,000,000 common shares for employee, director, and consultant incentives. Adopted by the board on November 4 to meet Nasdaq rules and tax code standards, it aligns interests with shareholders. Plan caps non-employee director grants at $100,000 value yearly.
10-Q
Q3 FY2025 results
RCM Technologies drove Q3 revenue to $70.3M, up 16.5% y/y from $60.4M while gross margin slipped to 27.6% from 29.6%. Engineering surged 30% to $31.4M on EPC and aerospace gains, Specialty Health Care climbed 13% to $30.0M via school contracts, but Life Sciences dipped 8% to $8.9M. Operating income held at $3.9M despite higher SG&A; diluted EPS matched at $0.30 on 7.6M shares. Cash fell to $1.3M after $7.5M OCF minus $1.4M capex, with $31.5M line of credit debt, $20.4M availability, and covenant compliance. Revenue hinges on two customers at 33% combined.
8-K
Q3 revenue surges 16.4%
RCM Technologies posted Q3 revenue of $70.3M, up 16.4% from $60.4M last year, with gross profit rising 8.8% to $19.4M. GAAP net income dipped to $2.3M or $0.30/share from $2.7M or $0.35/share, yet adjusted EBITDA held steady at $5.5M. Record 2026 Engineering backlog signals strength. Q4 poised for peak gross profit.
10-Q
Q2 FY2025 results
RCM Technologies posted solid Q2 FY2025 results, with revenue climbing 13.0% year-over-year to $78.2M, fueled by 15.9% growth in Specialty Health Care from school clients and 17.8% in Engineering via aerospace and energy projects, while Life Sciences dipped 9.3% on project timing. Gross margin held steady at 28.5%, but operating income rose 13.4% to $6.6M as SG&A efficiency offset investments; diluted EPS edged up to $0.50 from $0.47, reconciling cleanly with 7.5M weighted shares. Cash from operations reached $8.8M YTD, supporting $5.5M in share repurchases, with $5.5M cash and $20.8M revolver availability against $34.0M borrowings at 6.2% effective rate. No material M&A closed this quarter. Yet customer concentration persists, as two clients drove over 35% of revenue.
ACM
AECOM
98.35+0.39
CNTM
ConnectM Technology Solutions,
0.46-0.04
CTSH
Cognizant Technology Solutions
83.63-0.42
EME
EMCOR Group, Inc.
624.56+0.47
J
Jacobs Solutions Inc.
133.95-1.57
KBR
KBR, Inc.
42.59-0.49
RGP
Resources Connection, Inc.
5.21+0.05
RITR
Reitar Logtech Holdings Limited
1.21+0.11
RMTG
Regenerative Medical Technology
0.04+0.00
TTEK
Tetra Tech, Inc.
34.15-0.29